This year, 32 nonprofits providing essential services to Houstonians will receive grant funding from Houston Methodist. Photo courtesy of Houston Methodist

A Houston-area hospital system has announced the latest recipients of its grant program, benefiting nonprofits that are providing essential services to Houstonians.

Houston Methodist announced this month the 32 local nonprofit organizations receiving more than $6.8 million in community grants as a part of the Community Benefits Grant Program. This year, these nonprofits will give access to health care services to more than 188,000 individuals in underserved communities in the Greater Houston area.

“For three decades, the Houston Methodist Community Benefits Grant Program has helped create pathways to care for some of the most vulnerable in the Greater Houston community who often are struggling to afford basic necessities,” says Ryane Jackson, vice president of community benefits at Houston Methodist, in a news release.

Since the program's inception, it's provided $168 million to 82 local charities.

“Access to high quality health care is one of many issues that our community faces, and this grant helps makes much-needed health care resources affordable and accessible," she continues. "I’m proud that we can continue to partner with local organizations focused on expanding the health and well-being of all Houstonians.”

Houston Methodist announced the full list of this year’s Community Benefits grant awardees online.

Last year, Houston Methodist announced grants to 59 Houston-area nonprofit organizations totalling more than $4.6 million thanks to the Houston Methodist Diversity, Equity & Inclusion Grant Program.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”